ENO

Posology:

This product is intended to be used by adults (including the elderly) and children aged 12 years and over.

Paediatric Population:

Not suitable for children under 12 years of age.

Method of administration:

For oral administration. 5 g (one 5 ml spoonful of powder) or one sachet dissolved in a glass of water. Drink as symptoms occur. A second dose may be taken after 2-3 hours. Minimum dosing interval: 2 hours. Maximum daily dose (MDD): 2 x relevant dosage (5 g).

Maximum duration of antacid use is 14 days, unless advised by a physician.

Specific estimation of the frequency of adverse events for non-prescription products from post-marketing data is inherently difficult (particularly numerator data). On this basis, no estimate for MedDRA frequency categories is provided.

Gastrointestinal System SOC:

Minor gastrointestinal irritations, including belching, flatulence, and abdonminal distention. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellow card.

Do not exceed the recommended dose as excess or prolonged use may lead to alkalosis. Treatment should be discontinued if there is no improvement in conditions and medical advice should be sought. Persistent heartburn may be an early indicator of a more serious underlying condition.

Keep out of reach and sight of children.

3. g. those suffering from hypertension or congestive heart failure, should not use this product unless directed by a doctor. Patients with impaired hepatic and renal function. Sodium Carbonate + Sodium Bicarbonate + Citric Acid is contraindicated in patients with a prior hypersensitivity reaction to Sodium Carbonate + Sodium Bicarbonate + Citric Acid or any other ingredient of the preparation.